Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 2,0212,040 of 20,252 grants

Completed TRAINING, INDIVIDUAL
Uncovering the Role of RNA Modifications in the Paraspeckle
NATIONAL CANCER INSTITUTE Yale University United States 2023 – 2025

PROJECT SUMMARY RNA modifications are chemical changes made to transcripts that can regulate their processing, structure, and stability. Recent advances in modification detection t...

$476.9K
USD
Active TRAINING, INDIVIDUAL
Metabolic Obesity Phenotypes and Obesity-related Cancer Survival
NATIONAL CANCER INSTITUTE University of Utah United States 2023 – 2027

PROJECT SUMMARY. The incidence of obesity-related cancer (ORC) continues to increase rapidly despite a decrease in overall cancer incidence; currently ORCs constitute over 40% of a...

$358.5K
USD
Completed NON-SBIR/STTR RPGS
Synthetic manipulation of engineered perivascular niches
NATIONAL CANCER INSTITUTE University of Illinois At Urbana-Champai... United States 2023 – 2024

ABSTRACT This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 23-045. Glioblastoma (GBM) is the most common and lethal for...

$1.64M
USD
Completed NON-SBIR/STTR RPGS
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles
NATIONAL CANCER INSTITUTE Weill Medical Coll of Cornell Univ United States 2023 – 2025

Project Summary: High-risk prostate cancer (PC) is the second most common cause of cancer-related death in men. Improvements in overall survival and long-term morbidity will depend...

$4.31M
USD
Active NON-SBIR/STTR RPGS
Targeting PGC1β/PPARγ axis for overcoming acquired resistant to third generation EGFR-TKIs
NATIONAL CANCER INSTITUTE Emory University United States 2023 – 2028

SUMMARY Epidermal growth factor receptor (EGFR)-targeted therapy with EGFR tyrosine kinase inhibitors (EGFR-TKIs), particularly current third generation mutation-selective agents s...

$4.74M
USD
Active OTHER RESEARCH-RELATED
Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics
NATIONAL CANCER INSTITUTE University of Tx Md Anderson Can Ctr United States 2023 – 2026

PROJECT SUMMARY Shenqqing (Stan) Gu, Ph.D., is an experimental-computational biologist whose career goal is to develop personalized strategies for optimal combination immunotherapy...

$1.92M
USD
Completed NON-SBIR/STTR RPGS
Pathogenic Role of Foxl1+ Hepatic Progenitor Cells in Fibrotic Liver Disease
NATIONAL CANCER INSTITUTE Cincinnati Childrens Hosp Med Ctr United States 2023 – 2025

PROJECT SUMMARY/ABSTRACT Progression of chronic liver disease to fibrosis, cirrhosis, and cancer is the common course of several liver diseases, but treatments for the end-stage li...

$3.6M
USD
Completed NON-SBIR/STTR RPGS
Hormone signaling and translation control in advanced prostate cancer
NATIONAL CANCER INSTITUTE Fred Hutchinson Cancer Center United States 2023 – 2025

ABSTRACT (from parental grant) The recent advent of highly potent inhibitors of the androgen receptor and androgen biosynthesis has had the unfortunate iatrogenic effect of fueling...

$4.12M
USD
Completed NON-SBIR/STTR RPGS
Combining senescence-inducing and senolytic agents to improve melanoma therapy
NATIONAL CANCER INSTITUTE Ohio State University United States 2023 – 2025

Contact PD/PI: Vilgelm, Anna E Project Summary Metastatic melanomas are aggressive tumors that respond poorly to chemotherapy and radiation and promptly acquire resistance to targe...

$3.22M
USD
Completed NON-SBIR/STTR RPGS
Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2023 – 2025

PROJECT SUMMARY N/A Project Summary/Abstract

$3.82M
USD
Active OTHER RESEARCH-RELATED
Boosting IL-12-induced anti-glioblastoma activity via immunotherapeutic extracellular vesicles.
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2023 – 2026

PROJECT SUMMARY The objective of this application is to develop the career of Dr. Breyne, facilitating his transition to a stable, independent phase and establishing his research p...

$1.61M
USD
Completed NON-SBIR/STTR RPGS
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells
NATIONAL CANCER INSTITUTE Rutgers Biomedical and Health Sciences United States 2023 – 2025

ABSTRACT The human body is composed of at least 400 different cell types, each distinguishable by distinct cellular markers. Cancer cells also express distinct cellular markers, di...

$2.2M
USD
Completed NON-SBIR/STTR RPGS
Development of Caspase Cleavage Targeting Chimeras (CACTACs) for Targeted Protein Cleavage
NATIONAL CANCER INSTITUTE University of Texas Hlth Science Center United States 2023 – 2025

PROJECT SUMMARY Caspases are a family of cysteine proteases which can cleave proteins containing cleavage sites on the flexible region to trigger cell death through apoptosis or py...

$1.93M
USD
Completed NON-SBIR/STTR RPGS
Development of a novel, CNS-penetrant synthetic triterpenoid for pediatric high-grade glioma.
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2023 – 2025

PROJECT ABSTRACT This application is focused development of a new therapeutic for pediatric high-grade glioma (HGG), including a rare subset known as Diffuse Intrinsic Pontine Glio...

$2.26M
USD
Completed NON-SBIR/STTR RPGS
Identification and characterization of genetic risk factors in pediatric brain tumors
NATIONAL CANCER INSTITUTE Children'S Hosp of Philadelphia United States 2023 – 2025

PROJECT SUMMARY Brain tumors are the most common form of cancer in children between 0-19-years of age in the United States, and are the largest cause of cancer-related deaths. Our...

$1.78M
USD
Completed NON-SBIR/STTR RPGS
Novel TCR transgenic mice to study tumor neoantigen-specific T cell responses
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2025

PROJECT SUMMARY Activated CD8+ T cells are capable of responding to tumor neoantigens and can aid in the clearance of tumors. Indeed, CD8+ T cells are critical for the beneficial e...

$669.9K
USD
Active NON-SBIR/STTR RPGS
Rational targeting of Cdc42 to benefit immunotherapy
NATIONAL CANCER INSTITUTE Cincinnati Childrens Hosp Med Ctr United States 2023 – 2028

ABSTRACT T cells play important role in cancer cell immunosuppression. Cancer cells can interact with immune checkpoint proteins expressed on effector T cells to cause T cell exhau...

$5.94M
USD
Active NON-SBIR/STTR RPGS
Pyk2 regulates extracellular vesicles release in GBM cells and modulates activation of tumor infiltrating myeloid cells
NATIONAL CANCER INSTITUTE Universidad Central Del Caribe United States 2023 – 2026

Glioblastoma (GBM) is the most aggressive brain cancer and usually fatal within a year after diagnosis. Current treatment approaches provide only a modest, few months, life extensi...

$3.82M
USD
Completed NON-SBIR/STTR RPGS
c-Myc regulation by TGF-beta signaling as a therapeutic target in Osteosarcoma
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2023 – 2025

PROJECT SUMMARY Osteosarcoma (OS) is an aggressive malignant primary bone cancer with a high propensity for lung metastasis. Since the development of aggressive chemotherapy and su...

$805K
USD
Completed NON-SBIR/STTR RPGS
Targeting ULK3 for the treatment of triple negative breast cancer
NATIONAL CANCER INSTITUTE H. Lee Moffitt Cancer Ctr & Res Inst United States 2023 – 2025

PROJECT SUMMARY / ABSTRACT Clinical significance: Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and represents 15-20% of new cases (1). Given...

$842.5K
USD